Wellington Management Group’s Summit Therapeutics SMMT Stock Holding History

Wellington Management Group’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.44M	Buy	441,934 +79,076	+22%	+$1.4M	﹤0.01%	1404
2026 Q1	$6.88M	Buy	+362,858	New	+$5.87M	﹤0.01%	1339
2025 Q3	–	Sell	-39,694	Closed	-$845K	–	2093
2025 Q2	$845K	Sell	39,694 -798	-2%	-$18.2K	﹤0.01%	1744
2025 Q1	$781K	Buy	40,492 +373	+0.9%	+$7.48K	﹤0.01%	1759
2024 Q4	$716K	Sell	40,119 -4,069	-9%	-$78.9K	﹤0.01%	1782
2024 Q3	$968K	Sell	44,188 -223,964	-84%	-$3.13M	﹤0.01%	1716
2024 Q2	$2.09M	Sell	268,152 -29,468	-10%	-$159K	﹤0.01%	1504
2024 Q1	$1.23M	Buy	+297,620	New	+$1.18M	﹤0.01%	1631

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group's SMMT Position: Q2 2026 in Review

Wellington Management Group increased its Summit Therapeutics (SMMT) stake by 22% in Q2 2026, buying an estimated $1.4M and bringing the position to 441,934 shares worth $6.44M. The position accounts for ﹤0.01% of the portfolio, ranked #1404.

Wellington Management Group first reported a position in SMMT in Q1 2024 and has held it in 8 quarters since. The position peaked at $6.88M in Q1 2026. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Wellington Management Group held 441,934 shares of Summit Therapeutics worth $6.44M as of Q2 2026.
Wellington Management Group bought 79,076 Summit Therapeutics shares in Q2 2026, an estimated $1.4M.
Summit Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1404 holding.
Wellington Management Group first reported a position in Summit Therapeutics in Q1 2024 and has held it in 8 quarters since.
Wellington Management Group's Summit Therapeutics position peaked at $6.88M in Q1 2026.
243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.